admin

TORONTO, ONTARIO–(Marketwired – Sept. 27, 2017) – Revive Therapeutics Ltd. (“Revive” or the “Company”) (TSX VENTURE:RVV) (OTCQB:RVVTF), a company focused on the research, development and commercialization of novel treatments for serious and unmet medical needs, today announced that it has submitted an application to the U.S. Food and Drug Administration (“FDA”) seeking orphan drug designation […]

by

So what’s the next best contender? According to research, cannabis. A 2013 study published in the Journal of Substance Use Misuse found that people were self-medicating, in order to deal with and manage hyperactivity and impulsive — two major components of ADD/ADHD. The study surveyed about 280 cannabis users and the main finding was that a […]

by

She had no clue what she was in for, but certainly couldn’t have imagined this. Ellie Reid, a 26-year-old graduate student at the University of North Carolina at Chapel Hill, had one of the worst nights of her life—and all she did was eat a weed brownie. “I had no sense of the time. I […]

by

By Alicia Wallace, The Cannabist Staff Cannabidiol is a non-psychoactive cannabis compound touted for its medicinal promise — but marijuana- and hemp-derived extracts rich in CBD and low in intoxicating THC are facing a future yet to be determined. The Cannabist’s special report “CBD, TBD” explores the issues with CBD — federal-state conflicts, national drug […]

by

Zynerba Pharmaceuticals (ZYNE) shares skyrocketed last week as the company announced positive top-line data from a Phase 2 exploratory study. The top-line data was for Zynerba’s ZYN002, a transdermal cannabidiol gel, for the treatment of fragile X syndrome in pediatric patients. This is Zynerba’s 3rd press release regarding ZYN002 clinical trial results in the past […]

by

A market report by Ameri Research Inc. indicates that the global legal cannabis market was valued at $14.3 billion in 2016 and is projected to grow at a CAGR of 21.1% from 2017 to 2024. During the forecast period, the projected demand of cannabis will continue to rise for both recreational and medical use with estimated global […]

by

A market report by Ameri Research Inc. indicates that the global legal cannabis market was valued at $14.3 billion in 2016 and is projected to grow at a CAGR of 21.1% from 2017 to 2024. During the forecast period, the projected demand of cannabis will continue to rise for both recreational and medical use with estimated global […]

by

According to a research report by New Frontier Data, the legal cannabis market was worth an estimated $6.6 billion in 2016, and is projected to reach more than $24 billion by 2025 or growing at a compound annual growth rate (CAGR) of 16%. The medical cannabis market is expected to grow at 12% CAGR through 2025 […]

by

 Zynerba Pharmaceuticals, a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments, announced positive top line results from an open label exploratory Phase 2 FAB-C (Treatment of Fragile X Syndrome Anxiety and Behavioral Challenges with CBD) clinical trial evaluating ZYN002 cannabidiol (CBD) gel in pediatric and adolescent patients with Fragile X syndrome (FXS). The […]

by

The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in the field. … read more at: https://www.thepharmaletter.com/article/zx008-meets-phase-iii-goals-in-dravet-syndrome-trial

by

“Our leading media” are characterized by “indefensibly corrupt manipulations of language repeated incessantly.” Patrick Lawrence in The Nation, Aug. 9, 2017, on the media’s reporting of the alleged collusion between Donald Trump’s campaign and Russia To understand America’s crises today, one must first understand what has happened to two institutions: the university and the news […]

by

By Michael FitzhughStaff Writer Positive new pivotal data has shown that ZX-008, Zogenix Inc.’s re-imagining of a key component of the ill-fated obesity drug Fen-Phen, can significantly reduce seizure frequency in children with the rare genetic epilepsy, Dravet syndrome. The result kept Zogenix on track to seek U.S. and European approvals for the drug in […]

by